Bosutinib (Bosulif) is a kind of small molecule BCR-ABL and src TKI (Tyrosine Kinase Inhibitor), originally synthesized by Wyeth, and is being developed by Pfizer.
Bosutinib specifically originated in order to treat adult patients with chronic, accelerated, or blast phase Ph+ CML (Chronic Myelogenous Leukemia).
In the month of January, 2012, Pfizer announced FDA acceptance of a new drug application for bosutinib in order to treat patients with previously treated Ph+ Chronic Myeloid Leukemia.
In the month of September, 2012, the Food and Drug Administration approved bosutinib in order to treat CML (Chronic Myelogenous Leukemia).
In the month of December, 2017, the Food and Drug Administration approved Pfizer’s bosutinib in order to treat newly diagnosed patients with Ph+ Chronic Myelogenous Leukemia (CML).
The bosutinib price in India is around 10,629 INR for a supply of 30 tablets, depending on the wholesaler/pharmacy you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy bosutinib.
Sign in to leave a comment.